Adlai Nortye Ltd. America... (ANL)
NASDAQ: ANL
· Real-Time Price · USD
1.73
0.04 (2.37%)
At close: Aug 18, 2025, 3:50 PM
1.79
3.47%
After-hours: Aug 18, 2025, 04:10 PM EDT
2.37% (1D)
| Bid | 1.45 |
| Market Cap | 18.01M |
| Revenue (ttm) | 6.49M |
| Net Income (ttm) | -54.06M |
| EPS (ttm) | -1.62 |
| PE Ratio (ttm) | -1.07 |
| Forward PE | -4.38 |
| Analyst | Buy |
| Ask | 2.3 |
| Volume | 7,704 |
| Avg. Volume (20D) | 10,135.2 |
| Open | 1.76 |
| Previous Close | 1.69 |
| Day's Range | 1.61 - 1.80 |
| 52-Week Range | 1.10 - 3.89 |
| Beta | -0.88 |
Analyst Forecast
According to 0 analyst ratings, the average rating for ANL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 months ago · https://www.marketscreener.com
Adlai Nortye Ltd. Announces Topline Results of Phase III Buran Trial Evaluating Buparlisib in Combination with Paclitaxel for Recurrent or Metastatic HNSCCAdlai Nortye Ltd. announced topline results from its Phase III BURAN trial evaluating buparlisib (AN2025), a PI3K inhibitor, in combination with paclitaxel for the treatment of patients with recurrent...